# US 2026/0102434 A1 · High-performance mature intestinal organoid regenerative therapeutic agent derived from pluripotent stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0102434 A1
- Document ID: US20260102434A1
- Status: Published application
- Kind: A1
- Application number: 19/113,695
- Filed: 2023-09-20
- Published: 2026-04-16
- Earliest claimed: 2022-09-21
- Assignees: Korea Research Institute of Bioscience and Biotechnology
- Applicants: Korea Research Institute of Bioscience and Biotechnology
- Inventors: Mi-Young SON; Hana LEE; Eunho CHOI; Sohee PARK; Yubin HUH
- Web page: https://patentgrep.com/patent/US20260102434A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61K 35/38: Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- C12N 5/0656: {Adult fibroblasts}
- C12N 5/0658: {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}
- C12N 5/0662: {Stem cells}
- C12N 5/0679: {Cells of the gastro-intestinal tract}
- C12N 5/0697: {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N5/0691)}
- C12N 2500/60: Buffer, e.g. pH regulation, osmotic pressure
- C12N 2500/62: DMSO
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- C12N 2513/00: 3D culture
- C12N 2533/52: Fibronectin; Laminin
- C12N 2533/54: Collagen; Gelatin
- C12N 2533/56: Fibrin; Thrombin
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to a high-performance mature human intestinal organoid regenerative therapeutic agent derived from pluripotent stem cells. The high-performance mature human intestinal organoid regenerative therapeutic agent derived from pluripotent stem cells according to the present disclosure includes peristromal cell layers containing mesenchymal stromal cells, derived from the intestine, as the microenvironment around the intestine. That is, the high-performance mature human intestinal organoid regenerative therapeutic agent derived from pluripotent stem cells according to the present disclosure can exhibit high engraftment ability when transplanted together with peripheral cell layers around intestinal organoids and can exhibit superior regenerative ability through intestinal stem cells present in mature intestinal organoids, and therefore is likely to be useful as a regenerative therapeutic agent.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A pluripotent stem cell-derived intestinal organoid comprising a stromal cell layer around an intestinal organoid,
wherein the stromal cell layer around the intestinal organoid comprises mesenchymal stromal cells.

### Claim 30 (depends on 29)

The pluripotent stem cell-derived intestinal organoid comprising the stromal cell layer around the intestinal organoid of claim 29, wherein the stromal cell layer around the intestinal organoid further includes any one or more cells selected from the group consisting of smooth muscle cells, fibroblasts, myofibroblasts, telocytes, and pericytes.

### Claim 31 (depends on 29)

The pluripotent stem cell-derived intestinal organoid comprising the stromal cell layer around the intestinal organoid of claim 29, wherein the pluripotent stem cell-derived intestinal organoid comprising the stromal cell layer around the intestinal organoid is cultured by treatment with any one or more factors selected from the group consisting of IL-2, IL-22, IL-6, IL-1ß, IL-11, EGF, OSM, IL-10, NRG-1, and colivelin, and wherein the treatment with the factor is performed during differentiation into the intestinal organoid from the hindgut.

### Claim 32 (depends on 31)

The pluripotent stem cell-derived intestinal organoid comprising the stromal cell layer around the intestinal organoid of claim 31, wherein the pluripotent stem cell-derived intestinal organoid is cultured by treatment with IL-2.

### Claim 33 (depends on 29)

The pluripotent stem cell-derived intestinal organoid comprising the stromal cell layer around the intestinal organoid of claim 29, wherein the pluripotent stem cell-derived intestinal organoid comprising the stromal cell layer around the intestinal organoid, exhibits characteristics of a mature intestinal organoid.

### Claim 34 (depends on 33)

The pluripotent stem cell-derived intestinal organoid comprising the stromal cell layer around the intestinal organoid of claim 33, wherein the mature intestinal organoid has higher expression of any one or more factors selected from the group consisting of ASCL2, AXIN2, LGR5, and OLFM4, compared to pluripotent stem cell-derived immature intestinal organoids;
wherein the mature intestinal organoid has higher expression of any one or more factors selected from the group consisting of VIL1, KRT20, CHGA, MUC13, LYZ, OLFM4, SI, LCT, and DPP4, compared to pluripotent stem cell-derived immature intestinal organoids;
wherein the mature intestinal organoid has higher expression of any one or more factors selected from the group consisting of hCD31, CDH5, ECSCR, LYVE1, IGF2, VEGF, ANGPT1, and KDR, known as angiogenic factors and/or vascular endothelium-related factors, compared to adult stem cell-derived organoids or pluripotent stem cell-derived immature intestinal organoids;
wherein the mature intestinal organoid has higher expression of any one or more factors selected from the group consisting of IGF2, FOXF1, CXCL14, BMP4, IGFBP3, APOA1, PDGFRA, FOXF2, PTCH1, VEGFA, NKX2-3, BMP5, ITGA8, NRG1, ADAM28, COL4A5, and DLL1, compared to adult stem cell-derived organoids or pluripotent stem cell-derived immature intestinal organoids; and/or
wherein the mature intestinal organoid comprises hCD31+ vascular cells in the stromal cell layer around the intestinal organoid.

### Claim 35 (depends on 33)

The pluripotent stem cell-derived intestinal organoid comprising the stromal cell layer around the intestinal organoid of claim 33, wherein the stromal cell layer around the intestinal organoid comprises mesenchymal stromal cells, and the mesenchymal stromal cells exhibit at least one characteristic selected from the following:
(a) an enhanced expression level of hCD31 (PECAM1) compared to adult-derived mesenchymal stem cells, pluripotent stem cell-derived mesenchymal stem cells and/or immature intestinal organoid-derived mesenchymal stromal cells;
(b) enhanced expression levels of factors related to cellular vascular endothelial stimulation, angiogenesis, cell adhesion, and differentiation, compared to adult-derived mesenchymal stem cells, pluripotent stem cell-derived mesenchymal stem cells, and/or immature intestinal organoid-derived mesenchymal stromal cells;
(c) enhanced expression levels of endothelial cell types, compared to adult-derived mesenchymal stem cells, pluripotent stem cell-derived mesenchymal stem cells, and/or immature intestinal organoid-derived mesenchymal stromal cells;
(d) enhanced expression levels of endothelial cell characteristic factors on Gene Ontology (GO) term enrichment, compared to adult-derived mesenchymal stem cells, pluripotent stem cell-derived mesenchymal stem cells, and/or immature intestinal organoid-derived mesenchymal stromal cells;
(e) enhanced expression levels of angiogenic factors, vascular endothelial-related factors or vascular endothelial cell-related factors, compared to adult-derived mesenchymal stem cells, pluripotent stem cell-derived mesenchymal stem cells, and/or immature intestinal organoid-derived mesenchymal stromal cells;
wherein the angiogenic factor, vascular endothelial-related factor or vascular endothelial cell-related factor is any one or more selected from the group consisting of hCD31, CDH5, ECSCR, LYVE1, IGF2, VEGF, ANGPT1 and KDR,
(f) enhanced expression levels of any one or more selected from the group consisting of IGF2, FOXF1, CXCL14, BMP4, IGFBP3, APOA1, PDGFRA, FOXF2, PTCH1, VEGFA, NKX2-3, BMP5, ITGA8, NRG1, ADAM28, COL4A5, and DLL1, compared to adult-derived mesenchymal stem cells, pluripotent stem cell-derived mesenchymal stem cells, and/or immature intestinal organoid-derived mesenchymal stromal cells; and
(g) maintained expression levels of any one or more selected from the group consisting of αSMA, VIM and DESMIN at the time of subculture.

### Claim 36

A method for producing a pluripotent stem cell-derived mature intestinal organoid comprising a stromal cell layer around an intestinal organoid, the method comprising:
(a) culturing pluripotent stem cells in a medium containing any one or more selected from the group consisting of Nodal, Activin A, Activin B, BMP4, Wnt3a, and bFGF to perform differentiation into definitive endoderm;
(b) culturing the definitive endoderm in a medium containing: any one or more GSK3 inhibitors selected from the group consisting of BIO (6-bromoindirubin-3′-oxime), SB216763 (3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione), GSK-3β inhibitor VII (α,4-dibromoacetophenone), L803-mts (Myr-N-GKEAPPAPPQSpP-NH2), and CHIR99021; and a fibroblast growth factor (FGF), to perform differentiation into hindgut; and
(c) culturing the hindgut in a medium containing Noggin; epidermal growth factor (EGF); any one or more Wnt agonists selected from the group consisting of R-spondin 1, R-spondin 2, R-spondin 3, and R-spondin 4; and any one or more factors selected from the group consisting of IL-2, IL-22, IL-6, IL-1ß, IL-11, EGF, OSM, NRG-1, IL-10, and colivelin to produce a mature intestinal organoid.

### Claim 37 (depends on 36)

The method of claim 36, wherein in Step (a), the medium contains any one selected from the group consisting of Activin A, BMP4, bFGF and Wnt3a.

### Claim 38 (depends on 36)

The method of claim 36, wherein in Step (b), the medium contains CHIR99021 and FGF.

### Claim 39 (depends on 36)

The method of claim 36, wherein in Step (c), the medium contains Noggin; epidermal growth factor (EGF); R-spondin; and IL-2.

### Claim 40 (depends on 36)

The method of claim 36, wherein after differentiation into Hindgut in Step (b), in Step (c), any one or more factors selected from the group consisting of IL-2, IL-22, IL-6, IL-1ß, IL-11, EGF, OSM, NRG-1, IL-10, and colivelin are immediately added.

### Claim 41 (depends on 36)

The method of claim 36, wherein Step (c) is performed under Xeno-free conditions.

### Claim 42 (depends on 41)

The method of claim 41, wherein it is cultured with VitroGel.

### Claim 43

A method for treating an intestinal disease, comprising administering to a subject in need thereof the pluripotent stem cell-derived intestinal organoid comprising the stromal cell layer around the intestinal organoid,
wherein the stromal cell layer around the intestinal organoid comprises mesenchymal stromal cells.

### Claim 44 (depends on 43)

The method of claim 43, wherein the intestinal disease is any one or more selected from the group consisting of intestinal leakage syndrome, short bowel syndrome, irritable bowel syndrome, Crohn's disease, ulcerative colitis, intestinal Behcet's disease, infectious enteritis, ischemic bowel disease, and radiation enteritis.

### Claim 45 (depends on 43)

The method of claim 43, wherein the administering further comprises administration of at least any one biodegradable support selected from the group consisting of fibrin, laminin, collagen, gelatin, chitosan, alginate, hyaluronic acid, dextran, polylactic acid, poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (poly(PLGA)), poly-ε-(caprolactone), polyanhydride, polyorthoester, polyvinyl alcohol, polyethylene glycol, polyurethane, polyacrylic acid, poly-N-isopropylacrylamide, poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) copolymer, a copolymer thereof, and a mixture thereof

### Claim 46 (depends on 43)

The method of claim 43, wherein the pluripotent stem cell-derived intestinal organoid comprising the stromal cell layer around the intestinal organoid, exhibits characteristics of a mature intestinal organoid.

### Claim 47 (depends on 46)

The method of claim 46, wherein the mature intestinal organoid has higher expression of any one or more factors selected from the group consisting of ASCL2, AXIN2, LGR5, and OLFM4, compared to pluripotent stem cell-derived immature intestinal organoids;
wherein the mature intestinal organoid has higher expression of any one or more factors selected from the group consisting of VIL1, KRT20, CHGA, MUC13, LYZ, OLFM4, SI, LCT, and DPP4, compared to pluripotent stem cell-derived immature intestinal organoids;
wherein the mature intestinal organoid has higher expression of any one or more factors selected from the group consisting of hCD31, CDH5, ECSCR, LYVE1, IGF2, VEGF, ANGPT1, and KDR, known as angiogenic factors and/or vascular endothelium-related factors, compared to adult stem cell-derived organoids or pluripotent stem cell-derived immature intestinal organoids;
wherein the mature intestinal organoid has higher expression of any one or more factors selected from the group consisting of IGF2, FOXF1, CXCL14, BMP4, IGFBP3, APOA1, PDGFRA, FOXF2, PTCH1, VEGFA, NKX2-3, BMP5, ITGA8, NRG1, ADAM28, COL4A5, and DLL1, compared to adult stem cell-derived organoids or pluripotent stem cell-derived immature intestinal organoids; and/or
wherein the mature intestinal organoid comprises hCD31+ vascular cells in the stromal cell layer around the intestinal organoid.

### Claim 48 (depends on 46)

The method of claim 46, wherein the stromal cell layer around the intestinal organoid comprises mesenchymal stromal cells, and the mesenchymal stromal cells exhibit at least one characteristic selected from the following:
(a) an enhanced expression level of hCD31 (PECAM1) compared to adult-derived mesenchymal stem cells, pluripotent stem cell-derived mesenchymal stem cells and/or immature intestinal organoid-derived mesenchymal stromal cells;
(b) enhanced expression levels of factors related to cellular vascular endothelial stimulation, angiogenesis, cell adhesion, and differentiation, compared to adult-derived mesenchymal stem cells, pluripotent stem cell-derived mesenchymal stem cells, and/or immature intestinal organoid-derived mesenchymal stromal cells;
(c) enhanced expression levels of endothelial cell types, compared to adult-derived mesenchymal stem cells, pluripotent stem cell-derived mesenchymal stem cells, and/or immature intestinal organoid-derived mesenchymal stromal cells;
(d) enhanced expression levels of endothelial cell characteristic factors on Gene Ontology (GO) term enrichment, compared to adult-derived mesenchymal stem cells, pluripotent stem cell-derived mesenchymal stem cells, and/or immature intestinal organoid-derived mesenchymal stromal cells;
(e) enhanced expression levels of angiogenic factors, vascular endothelial-related factors or vascular endothelial cell-related factors, compared to adult-derived mesenchymal stem cells, pluripotent stem cell-derived mesenchymal stem cells, and/or immature intestinal organoid-derived mesenchymal stromal cells;
wherein the angiogenic factor, vascular endothelial-related factor or vascular endothelial cell-related factor is any one or more selected from the group consisting of hCD31, CDH5, ECSCR, LYVE1, IGF2, VEGF, ANGPT1 and KDR,
(f) enhanced expression levels of any one or more selected from the group consisting of IGF2, FOXF1, CXCL14, BMP4, IGFBP3, APOA1, PDGFRA, FOXF2, PTCH1, VEGFA, NKX2-3, BMP5, ITGA8, NRG1, ADAM28, COL4A5, and DLL1, compared to adult-derived mesenchymal stem cells, pluripotent stem cell-derived mesenchymal stem cells, and/or immature intestinal organoid-derived mesenchymal stromal cells; and
(g) maintained expression levels of any one or more selected from the group consisting of αSMA, VIM and DESMIN at the time of subculture.
